Clinical Outsourcing Strategies 2017 Participant Bio/Pharma Companies

Exhibition & Sponsorship Enquiry From

Required

Required

Required

Submitting Form...

The server encountered an error.

Form received.

Required

Why Exhibit or Sponsor the COS symposium:

 

 

COS has been in motion as an annual event for several years serving a platform for Service and Solution providers catering to clinical trials across all phases.  However the primary purpose of the symposium is content. The conference explores End – to – End Clinical Trial Outsourcing, focusing on a balanced mixture of Clinical Outsourcing and Clinical Operations.

 

With pharmaceutical, Biopharmaceuticals, Biotechs and Academic Partnership representatives presenting in-depth perspectives on optimal approach to clinical trial outsourcing and operations.

 

The platform has proven pivotal for all exhibiting and sponsoring companies in demonstrating offerings Clinical Outsourcing and Clinical Operational decision and budget holders. While sponsoring (pharma) companies have found the in-depth meetings and personalized agenda of most interest in managing on-site daily activities.  As a clinical research organization you can expect a pre-scheduled 1-2-1 meetings in your private area.  And engaging with traffic to allow sampling, showcasing of your capabilities and capacities as a Clinical Trial Service provider.  Tenders have been allocated subject to such meetings.  The opportunity is provided to you to raise awareness of your company and your contributions to the industry with products and services you provide, surrounded by sponsors, business associates and partners.

 

 

You may wish to engage COS 2017 Symposium based on showcasing, mass education and or as branding initiative, we recommend that you make a direct enquiry.

 

 

 

> FREE WEBINAR REGISTRATION

What's

available for 2018?

 

> PREARRANGED 1-TO-1 MEETINGS

> Free registration to a series of webinars dedicated in clinical outsourcing & operations and conducted by the industry's experts

> Learn more and benefit from 1-to-1 prearranged meetings between pharmaceuticals and CROs in a private space.

Sponsorship/Exhibition

Over 10,000 qualified tissue specimens available for use by public and private research organizations. All diseases and organs - selectable based on your needs.

 

1st FRENCH PATHOLOGY BIOBANK

MEDIPATH collects, stores and gives access to a vast selection of biological pathology samples via its tumor bank: France Tissue Bank® Specimens & Data. MEDIPATH has been granted authorization for specimens sourcing activity by the French Ministry of Higher Education, Research and Innovation (“Authorization No. AC-2016-2707”

Over 40 pathologists from 9 different sites Over 500,000 files including 25,000 diagnosed cancer cases per year Over 50 healthcare institution partners Over 5,000 connected clinicians 1st French facility accredited NF EN ISO 15189 by Cofrac. Accreditation No. 8-3052, scope and sites available on www.cofrac.fr Participation to recognized, independent, French (AFAQAP) and international (UK-NEQAS, QCMD) quality programs/surveys Member of the panel of experts on rare diseases of the French National Cancer Institute (INCa)

 

With more than 200,000 tissue/ biopsy specimens and more than 300,000 liquid cytology specimens characterized each year, Medipath provides a biobank of biological tumor samples (tissue, slides, pap smears) for a wide range of organs and diseases.

 

France Tissue Bank® Specimens & Data A database containing more than 10,000 FFPE pathological and normal tissue specimens (primary tumors and metastases, inflammatory diseases) from all organs and diseases A wide range of liquid-based cytology specimens Two data types: raw biological pathology material or characterized by our pathologists Data stored and provided according to applicable regulations

 

WHY usinG France Tissue Bank® Specimens & Data? a Our CONFideNtiaLitY regardiNg • Personal information (data privacy agreement, anonymized specimens, secured data system) • Your research activities (non-disclosure agreement, contracts between interested parties: material transfer agreement (MTA) or collaboration agreement) a The QuaLitY of the specimens and related data (implementation of good practices, indicatorbased quality control of all processes) a aCCeSS to biological pathology resources a Our reSpONSiVeNeS

- Premier Research Group Ltd , provides clinical development services to biotech and specialty pharma companies worldwide. Its services include clinical monitoring, project management, clinical research, late phase (phase IV) research, data management, biostatistics, regulatory affairs, medical affairs, pharmacovigilance, technology, strategic sourcing, interactive voice/Web response system, medical writing, and quality assurance. The company offers clinical development programs with a focus on addressing unmet needs in areas, such as analgesia, hematology/oncology, neuroscience, pediatrics, cardiovascular, medical device and diagnostics, and rare diseases.

 

Premier Research is not about being everything to everyone. Instead, our deep, focused expertise targets the therapeutic areas and indications where today’s biotech and specialty pharma pioneers are doing the most amazing work. We’re 1,000 employees strong and operate in more than 20 countries, delivering unmatched expertise, operational skills, and dedication to meeting customers’ most challenging needs.

 

Premier Research Group Ltd. was founded in 2002 and has locations in United Kingdom, Australia, Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Italy, Poland, Romania, the Russian Federation, Slovak Republic, Spain, Ukraine, and the United States.

 

“As a global CRO I can inform you that we have sponsored for several years, and the 1-2-1 meetings are the only reason we are returning annually. It simply works for us and as stated previously we will support the 2017 symposium.”